[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"attr-amyloidosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:attr-amyloidosis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,60,84],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100405602","conttribute-a-global-observational-study-of-patients-with-transthyretin-ttr-mediated-amyloidosis-attr-amyloidosis-100405602",false,"NCT04561518","ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)","ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)","ConTTRibute","Inclusion Criteria:\n\n* Diagnosis of ATTR amyloidosis or documented known disease-causing TTR variant for the cohort of pre-symptomatic carriers\n* Germany Only: Patients must be treated per the summary of product characteristics (SmPC) for any approved treatment for ATTR amyloidosis\n\nExclusion Criteria:\n\n* Current enrollment in a clinical trial for any investigational agent","ALL",{"count":19,"type":20},1500,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to:\n\n* Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients\n* Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting\n* Describe disease emergence\u002Fprogression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant",[24,25],"Transthyretin-Mediated Amyloidosis","ATTR Amyloidosis",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46],"RNAi therapeutic","Transthyretin","TTR","Amyloidosis","Hereditary Transthyretin-mediated (hATTR) Amyloidosis","hATTR amyloidosis","Hereditary ATTR amyloidosis","Wild-type amyloidosis","wtATTR amyloidosis","ATTRv amyloidosis","ATTRwt amyloidosis","Polyneuropathy","Familial amyloid polyneuropathies","ATTR","Transthyretin amyloidosis","TTR-mediated amyloidosis","Polyneuropathies","Amyloid neuropathies","Amyloid neuropathies, familial","Amyloidosis, familial","RECRUITING","2026-05-27",{"date":50,"type":51},"2026-05-29","ACTUAL",{"date":53,"type":51},"2020-11-23",{"date":55,"type":20},"2033-12-31",{"name":57,"class":58},"Alnylam Pharmaceuticals","INDUSTRY",40,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":68,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":70,"conditions":71,"keywords":72,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100543443","overtture-characteristics-treatment-patterns-and-outcomes-of-patients-with-attr-amyloidosis-100543443","NCT06355934","OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis","OverTTuRe: An Observational Multi-Country Study Collecting Real-World Secondary Data on the Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis","OverTTuRe","Inclusion Criteria:\n\n* Patients aged \\>18 years at study index date AND\n* A reported diagnosis code for amyloidosis OR\n* A claim for ATTR-specific treatment OR\n* A positive biopsy for amyloidosis and positive immunostaining result of biopsy for ATTR\n\nExclusion Criteria:\n\n* Evidence of primary (AL) and secondary (AA) amyloidosis AND\u002FOR\n* At least one claim\u002Fprocedure code for stem cell transplant or at least two claims\u002Fprocedure codes for chemotherapy and autoimmune disease drugs which may represent AL (primary) or AA (secondary) amyloidosis treatments",{"count":69,"type":20},52121,"The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns and selected clinical, economic, and humanistic outcomes (for example Health Related Quality of Life (HRQoL), Neuropathy impairment score, activities of daily living (ADL) assessments) in patients with ATTR amyloidosis, and to better understand how the disease is presented.",[25],[73],"ATTR-CM, ATTRv-PN","2026-05-18",{"date":76,"type":51},"2026-05-19",{"date":78,"type":51},"2023-08-21",{"date":80,"type":20},"2026-09-30",{"name":82,"class":58},"AstraZeneca",26,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":96,"studyType":21,"phases":4,"briefSummary":97,"conditions":98,"keywords":99,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":112},"100473440","the-italian-transthyretin-amyloidosis-web-network-100473440","NCT05444920","The Italian Transthyretin Amyloidosis Web-Network","The Italian Transthyretin Amyloidosis Web-Network (ITA-WebNet)","ITA-WebNet","Inclusion Criteria:\n\n1. Suspected diagnosis of systemic and localized amyloidosis;\n2. age .18 years;\n3. ability to understand and willingness to sign an informed consent (patients who already sign informed consent for clinical data to be used in retrospective analyses will be accepted);\n4. planned (or ongoing) follow-up at participating center.\n\nExclusion Criteria:\n\n1\\. Diagnosis of light chain (AL) amyloidosis","18 Years","99 Years",{"count":95,"type":20},1000,"5 Years","The study aims, by generating a large registry of patients with ATTR amyloidosis, including data at diagnosis and during follow up, to describe the natural history of ATTR amyloidosis in a real-world setting and to define and validate prognostic models, response criteria applicable at any point of the disease. The registry will also be used for data sharing and to allow the possibility of a close collaboration amongst the amyloidosis experts of the ARTC and all the physicians around the Country involved in the diagnosis and management of systemic amyloidosis. Thanks to the online registry, the diagnostic facility of the ARTC will be made available to requesting physicians.",[25],[100,101],"amyloidosis","systemic amyloidosis","2026-03-23",{"date":104,"type":51},"2026-03-27",{"date":106,"type":51},"2022-07-13",{"date":108,"type":20},"2027-11-01",{"name":110,"class":111},"Fondazione IRCCS Policlinico San Matteo di Pavia","OTHER",30]